EU averts delays to new drug approvals
This article was originally published in SRA
A potential 30-day delay to the issuing of new European Union marketing authorisations has been avoided after MEPs voted to shorten the statutory scrutiny period given to the European Parliament as part of the EU decision-making process1-3.
You may also be interested in...
A number of countries are resorting to extreme measures such as export bans to preserve stocks of medicines for the COVID-19 pandemic. Belgium is among the latest to impose an export prohibition, but might it fall foul of the EU’s export regulations?
In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.